CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
Residual doubts: Carving up common impact in the turkey class certification decision
In the article, “Residual Doubts: Carving Up Common Impact in the Turkey Class Certification Decision,” published by the American Bar Association (ABA), CRA’s...